Oxurion N.V.
OTC: TBGNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Graney
- Employees
- 27
- Headquarters
- Leuven, Belgium
- IPO year
- 2007
- Market cap
- $433.7M
- Website
- https://www.oxurion.com
Loading TBGNF…
Loading profile data…Frequently asked questions about TBGNF
What does Oxurion N.V. (TBGNF) do?
Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline inc...
Where does TBGNF trade?
Oxurion N.V. (TBGNF) trades on the Other OTC.
What sector is TBGNF in?
Oxurion N.V. (TBGNF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oxurion N.V.?
Thomas Graney is the chief executive officer of Oxurion N.V. (TBGNF).
Where is Oxurion N.V. headquartered?
Oxurion N.V. is headquartered in Belgium.
Does TBGNF pay a dividend?
Oxurion N.V. (TBGNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TBGNF go public?
Oxurion N.V. (TBGNF) completed its initial public offering in 2007.